ArriVent BioPharma Secures Global Rights to Promising Cancer Drug MRG007 in $1.2B Deal

Retrieved on: 2025-01-22 00:03:30

Tags for this article:

Click the tags to see associated articles and topics

ArriVent BioPharma Secures Global Rights to Promising Cancer Drug MRG007 in $1.2B Deal. View article details on hiswai:

Excerpt

ArriVent BioPharma (AVBP) has secured an exclusive global license agreement with Lepu Biopharma for MRG007, a novel antibody drug conjugate (ADC) ...

Article found on: www.stocktitan.net